The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 1, 2008, Pages 99-105

  Zhang, Shuang Qing ^a,c   Zhong, Xu Ying ^a   Chen, Guo Hua ^b   Lu, Wan Liang ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BIS(MALTOLATO)OXOVANADIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FEMUR; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; MALE; NONHUMAN; PHARMACOKINETICS; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ALLOXAN; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMUR; HALF-LIFE; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY; MALE; PYRONES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VANADATES;

EID: 38349173400     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.1.0013     Document Type: Article

References (23)

1. Cantley, L. C., Josephson, L., Warner, R., Yanagisawa, M., Lechene, C., Guidotti, G. (1977) Vanadate is a potent (Na,K)-ATPase inhibitor found in ATP derived from muscle. J. Biol. Chem. 252: 7421-7423
2. Cohen, N., Halberstam, M., Shlimovich, P., Chang, C. J., Shamoon, H., Rossetti, L. (1995) Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non insulin dependent diabetes mellitus. J. Clin. Invest. 95: 2501-2509
3. +)-ATPase inhibitor. J. Biol. Chem. 255: 5306-5312
4. Fugono, J., Yasui, H., Sakurai, H. (2001) Pharmacokinetic study on gastrointestinal absorption of insulinomimetic vanadyl complexes in rats by ESR spectroscopy. J. Pharm. Pharmacol. 53: 1247-1255
5. Goldfine, A. B., Simonson, D. C., Folli, F., Patti, M. E., Kahn, C. R. (1995) In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol. Cell. Biochem. 153: 217-231
6. Liboiron, B. D., Thompson, K. H., Hanson, G. R., Lam, E., Aebischer, N., Orvig, C. (2005) New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals. J. Am. Chem. Soc. 127: 5104-5115
7. McNeill, J. H., Yuen, V. G., Hoveyda, H. R., Orvig, C. (1992) Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. J. Med. Chem. 35: 1489-1491
8. Monaco, L., Geffken, G., Silverstein, J. H. (1996) Accuracy of injection site identification among children with insulin dependent diabetes mellitus: a comparison of traditional and new visual aids. Clin. Pediatr. 35: 191-197
9. Nagaoka, M. H., Yamazaki. T., Maitani, T. (2002) Binding patterns of vanadium ions with different valence states to human serum transferrin studied by HPLC/high-resolution ICP-MS. Biochem. Biophys. Res. Commun. 296: 1207-1214
10. Reul, B. A., Amin, S. S., Buchet, J. P., Ongemba, L. N., Crans, D. C., Brichard, S. M. (1999) Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Br. J. Pharmacol. 126: 467-477
11. Sakurai, H. (2002) A new concept: the use of vanadium complexes in the treatment of diabetes mellitus. Chem. Rec. 2: 237-248
12. 48V-labeled compounds in rats. J. Appl. Physiol. 84: 569-575
13. Shechter, Y. (1990) Insulin-mimetic effect of vanadate. Possible implications for future treatment of diabetes. Diabetes 39: 1-5
14. Srivastava, A. K. (2000) Anti-diabetic and toxic effects of vanadium compounds. Mol. Cell. Biochem. 206: 177-182
15. Srivastava, A. K., Mehdi, M. Z. (2005) Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet. Med. 22: 2-13
16. Thompson, K. H., Liboiron, B. D., Sun, Y., Bellman, K. D., Setyawati, I. A., Patrick, B. O., Karunaratne, V., Rawji, G., Wheeler, J., Sutton, K., Bhanot, S., Cassidy, C., McNeill, J. H., Yuen, V. G., Orvig, C. (2003) Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential. J. Biol. Inorg. Chem. 8: 66-74
17. Thompson, K. H., Barta, C. A., Orvig, C. (2006) Metal complexes of maltol and close analogues in medicinal inorganic chemistry. Chem. Soc. Rev. 235: 545-556
18. Tsiani, E., Fantus, I. G. (1997) Vanadium compounds. Biological actions and potential as pharmacological agents. Trends. Endocrinol. Metab. 8: 51-58
19. Willsky, G. R., Goldfine, A. B., Kostyniak, P. J., McNeill, J. H., Yang, L. Q., Khan, H. R., Crans, D. C. (2001) Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV). J. Inorg. Biochem. 85: 33-42
20. Yuen, V. G., Orvig, C., McNeill, J. H. (1993) Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). Can. J. Physiol. Pharmacol. 71: 263-269
21. Yuen, V. G., Orvig, C., McNeill, J. H. (1995) Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium (IV) following acute and chronic administration. Can. J. Physiol. Pharmacol. 73: 55-64
22. Yuen, V. G., Vera, E., Battell, M. L., Li, W. M., McNeill, J. H. (1999) Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats. Diabetes. Res. Clin. Pract. 43: 9-19
23. Zhang, S. Q., Zhong, X. Y., Lu, W. L., Zheng, L., Zhang, X., Sun, F., Fu, G. Y., Zhang, Q. (2005) Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. J. Inorg. Biochem. 99: 1064-1075